Literature DB >> 12182745

Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.

D Boixeda1, F Bermejo, C Martín-De-Argila, A López-Sanromán, V Defarges, F Hernández-Ranz, J M Milicua, A García-Plaza.   

Abstract

AIM: To study the efficacy of a 7-day quadruple regimen combining pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection after failure of standard triple therapy.
METHODS: A prospective study was made of 140 patients infected with H. pylori and diagnosed with peptic ulcer or non-ulcer dyspepsia in whom triple therapy with proton pump inhibitor, clarithromycin and amoxicillin had failed. The patients were treated with quadruple therapy including pantoprazole, 40 mg twice daily, colloidal bismuth subcitrate, 120 mg four times daily, tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily, for 7 days. Two months after completion of therapy, a 13C-urea breath test was performed to confirm eradication.
RESULTS: With quadruple therapy, the H. pylori eradication rates were 82% (95% confidence interval (CI), 75-88%) by 'intention-to-treat' and 85% (95% CI, 79-91%) by 'per protocol'. No major side-effects were observed. No differences in eradication success were observed in relation to underlying disease (peptic ulcer: 85% (95% CI, 76-91%) vs. non-ulcer dyspepsia: 83% (95% CI, 68-93%)) or smoking habits (smokers: 86% (95% CI, 75-93%) vs. non-smokers: 83% (95% CI, 71-91%)).
CONCLUSION: Quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole for 7 days is an effective H. pylori eradication treatment for patients in whom standard triple therapy has failed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182745     DOI: 10.1046/j.1365-2036.2002.01304.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

1.  Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails.

Authors:  Ulrich R M Bohr; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

Review 3.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.

Authors:  Siok-Siong Ching; Sivakumaran Sabanathan; Lloyd-R Jenkinson
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

5.  Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.

Authors:  José M Navarro-Jarabo; Nuria Fernández; Francisca L Sousa; Encarnación Cabrera; Manuel Castro; Luz M Ramírez; Robin Rivera; Esther Ubiña; Francisco Vera; Isabel Méndez; Francisco Rivas-Ruiz; José L Moreno; Emilio Perea-Milla
Journal:  BMC Gastroenterol       Date:  2007-07-25       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.